PCN2: DOSES OF OLANZPINE, RISPERIDONE, AND HALOPERIDOL IN CLINICAL PRACTICE: RESULTS OF A PROSPECTIVE PHARMACOEOPIDEMIOGICAL STUDY (EFESO) | Publicación